Clene to Present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

Rhea-AI Summary

Clene Inc. (Nasdaq: CLNN), a clinical-stage biopharmaceutical company focusing on neurodegenerative diseases, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase. The event is scheduled for August 13, 2024, with Clene's presentation set for 11:30 am EST.

Clene specializes in improving mitochondrial health and protecting neuronal function to treat conditions such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). The company's management will deliver a presentation and host one-on-one investor meetings during the conference.

Interested parties can access a webcast of the presentation through Clene's website in the 'Events' section or via a provided registration link.

SALT LAKE CITY, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Canaccord Genuity 44^th Annual Growth Conference & Private Company Showcase and host 1x1 investor meetings.

Date: August 13, 2024
Time of Presentation: 11:30 am EST
Format: Presentation
1x1 Meetings: Please contact your Canaccord representative.

A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register online to view the webcast here: link.

About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8^® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8^® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X and LinkedIn.

Contacts:

Media Contact Ignacio Guerrero-Ros, Ph.D., or David Schull Russo Partners, LLC Ignacio.guerrero-ros@russopartnersllc.com David.schull@russopartnersllc.com (858) 717-2310

Investor Contact Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com 617-283-2856

FAQ

When is Clene Inc. (CLNN) presenting at the Canaccord Genuity Conference?

Clene Inc. (CLNN) is presenting at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase on August 13, 2024, at 11:30 am EST.

What diseases does Clene Inc. (CLNN) focus on treating?

Clene Inc. (CLNN) focuses on treating neurodegenerative diseases, specifically amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).

How can investors access Clene's (CLNN) presentation at the Canaccord Genuity Conference?

Investors can access a webcast of Clene's (CLNN) presentation through the 'Events' section of the company's website or by registering online via the provided link.

Will Clene Inc. (CLNN) be hosting one-on-one meetings at the Canaccord Genuity Conference?

Yes, Clene Inc. (CLNN) will be hosting one-on-one investor meetings at the Canaccord Genuity Conference. Interested parties should contact their Canaccord representative to arrange a meeting.